Pharmaceutical

China’s NMPA prioritises HUTCHMED’s lung cancer therapy review

China NMPA has granted acceptance and priority review for the NDA for HUTCHMED’s ORPATHYS (savolitinib) and TAGRISSO (osimertinib) combination

Jan 4, 2025 - 06:00
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
China NMPA has granted acceptance and priority review for the NDA for HUTCHMED’s ORPATHYS (savolitinib) and TAGRISSO (osimertinib) combination
Read the original article

Tags:

Previous Article

SIGA’s antiviral approved in Japan for orthopoxvirus treatment

Next Article

Neumora shares sink following Phase III flop in MDD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Race for a first-to-market therapy for NASH heats up

Race for a first-to-market therapy for NASH heats up

Mar 21, 2023

Suicide hotlines promise anonymity. Dozens of their websites send sensitive data to Facebook

Suicide hotlines promise anonymity. Dozens of their web...

Jun 14, 2023

Why do some women experience UTI pain with no clear infection? A mouse study offers clues

Why do some women experience UTI pain with no clear inf...

Mar 2, 2024